DWN12088 not checked

Daewoong Pharmaceutical Co. LTD.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total

What this is

How it works
How it works isn't classified yet
Tested for
Idiopathic Pulmonary Fibrosis
Main trialPhase 2
“This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.”In the company’s words, NCT05389215 on ClinicalTrials.gov

Other drugs for Idiopathic Pulmonary Fibrosis

All 42 drugs for Idiopathic Pulmonary Fibrosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 13 Oct 2026 Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Phase 1Completed 12 Jul 2021 To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
Phase 1Completed 2 Aug 2021 To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DWN12088

Following is part of Solo: you see every change to DWN12088 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in